Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 495-496 (2020)



This article was written on behalf of the IRDiRC ODDG Task Force and Therapies Scientific Committee. The members and contributors beyond the authors were A. Aiuti, D. Athanasiou, L. Conklin, S. Cheng, R. Conwit, M. Driessens, M. Haffner, E. Hoffman, S. Jethwa, E. Matsuki, A. Mingorance, T. Morel, A. Pariser, C. Pontes, M. Scarpa and R. Yang. We would also like to thank A.-L. Pham-Hung d’Alexandry d’Orengiani for her support. The work was supported by the European contracts “SUPPORT-IRDiRC” (N° 305207) and “European Joint Programme on Rare Diseases”(N°825575).


The views expressed in this article are the personal views of the author(s) and may not be understood as being made on behalf of their employer(s)/organization(s).


  1. Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020).

    Article  PubMed  Google Scholar 

  2. Boycott, K. M. & Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat. Rev. Drug Discov. 17, 151–152 (2018).

    Article  PubMed  Google Scholar 

  3. Austin, C. P. et al. Future of rare diseases research 2017–2027: An IRDiRC perspective. Clin. Transl. Sci. 11, 21–27 (2018).

    Article  PubMed  Google Scholar 

  4. Day, S. et al. Recommendations for the design of small population clinical trials. Orphanet J. Rare Dis. 13, 195 (2018).

    Article  PubMed  Google Scholar 

  5. Morel, T. et al. Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J. Rare Dis. 12, 171 (2017).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary figures

Competing Interests

The authors declare no competing interests.

Nature Careers


  • Fully-funded PhD positions on perovskite and tandem solar cell - ANU - world's top 30 university

    Join a world-class photovoltaics research group, contribute to the development of the next generation of solar cells at ANU- world's top 30 university

    Canberra, Australian Capital Territory (AU)

    The Australian National University- School of Engineering

  • Assistant Professor

    The Division of Immunobiology within the Department of Pathology and Immunology at Washington University School of Medicine in St. Louis is seeking...

    Saint Louis, Missouri

    Washington University in Saint Louis Division of Immunobiology

  • Become a Harvard Radcliffe Institute Fellow

    Harvard Radcliffe Institute fellows are exceptional scientists, writers, s...

    Cambridge, Massachusetts

    Harvard Radcliffe Institute

  • Associate or Senior Editor

    Position: Associate or Senior Editor Location: NYC or Berlin - Hybrid working model Deadline: August 27th, 2024   JOB SUMMARY: Nature, the internat...

    New York City, New York (US)

    Springer Nature Ltd

  • Locum Associate or Senior Editor, Nature Neuroscience

    Locum Associate or Senior Editor, Nature Neuroscience Line manager Chief Editor, Nature Neuroscience Location: NYC, Berlin Deadline: August 5th, 20...

    New York (US)

    Springer Nature Ltd

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links